$QBIO is our New Low-float, BioTech Alert w/ MASSIVE UPSIDE!
=====================
QBIO (Q BioMed Inc.)
Alert Price: $1.77
Float: 9.2M
Investor Presentation
Fact Sheet
Shareholder Update
Corporate Update Video
========================
Members,
We hope you enjoyed the over +23% in realistic profit that Wednesday's alert provided.
Earlier today, we told you that we had identified a company operating in the biotech space that looks primed and ready to breakout for some significant gains in the immediate future.
Please turn your immediate attention to QBIO (Q BioMed Inc.).
This biomedical acceleration and development company appears to be extremely undervalued and oversold at the moment, and we want our members to be on board for what we believe will be an epic bullish reversal in Q1 2019.
The company has several bullish catalysts working in its favor that we believe will help make it a significant winner for our members:
The biotech sector as a whole has been on fire, and is up over +20% since December 24th.
Strong corporate leadership led by CEO Denis Coran.
A growing pipeline and strategy that mitigates risk & drives shareholder value.
Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.
QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3.
QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential.
QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.
Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th.
At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility.
Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally!
This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!
This would be huge news, and could have a major impact on QBIO's stock price.
This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment.
We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace.
Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value.
This has the potential to be our next big winner of Q1 2019.
As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
About Q BioMed
Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.
QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.
Q BioMed Unlocks Undiscovered Biomedical Value
Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
Licenses or acquires the assets and works together to create valuation growth
How Q BioMed Accelerates Biomedical Technology Development
Unlocks capital in US public markets to fund the development of assets
Makes liquid investments in high-value assets that can produce exponential returns
Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships
Recent Developments
Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001
On Wednesday, QBIO announced that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
Dr. Ventola serves as a clinical psychologist and assistant professor at Yale University's Child Study Center with a clinical and research focus in: behavioral treatment for autism spectrum disorders, Pivotal Response Treatment (PRT), biological markers of treatment response, and dissemination and implementation of treatment for ASD. Dr. Ventola also directs the Rare Disease and Pediatric Center of Excellence at Cogstate, a publicly traded company that supports pharmaceutical companies in clinical trial design, methodologies, and rater training services as it relates to cognitive and other clinical outcome assessments.
Strategy and Clinical Trial Design Specialist Provides Expertise for the Clinical Trial Design and Regulatory Requirements of QBM-001
QBM-001 Developed to Treat a Pediatric Non-Verbal Disorder which impacts 18,000 children each year in the U.S and a similar amount in Europe.
Market Outlook
The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
Bone Metatases from Prostate and Breast Cancer
450,000 new breast and prostate cancer diagnoses each year
1 in 3 people will develop bone metastases from the spread of breast and prostate cancer
Pediatric Non-Verbal Disorder
Among the >60,000 US children who develop Autism Spectrum Disorders (ASD)
every year,
20,000 become nonverbal and will have to rely on assisted living for the rest of
their life.
Liver Cancer
700,000 patients worldwide
Short 1-year survival rate
Estimated 39,230 adults in the US will be diagnosed every year
Glaucoma
60 million patients worldwide
8 million with bilateral blindness
Typically no early warning signs
Therapy only slows progression, no cure
Technical Analysis
QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk.
CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend.
QBIO is trading well off its 52-week high, with plenty of room to the upside.
In fact, a run back to its 52-week high of $4.50 would represent a gain of over +154%!
The float on QBIO is also very thin at just $1.77, so don't be surprised if we see a big move from this ticker tomorrow.
As we stated above, this could easily be our next big winner of Q1 2019.
We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
QBIO (Q BioMed Inc.)
Alert Price: $1.77
Float: 9.2M
Investor Presentation
Fact Sheet
Shareholder Update
Corporate Update Video
========================
Members,
We hope you enjoyed the over +23% in realistic profit that Wednesday's alert provided.
Earlier today, we told you that we had identified a company operating in the biotech space that looks primed and ready to breakout for some significant gains in the immediate future.
Please turn your immediate attention to QBIO (Q BioMed Inc.).
This biomedical acceleration and development company appears to be extremely undervalued and oversold at the moment, and we want our members to be on board for what we believe will be an epic bullish reversal in Q1 2019.
The company has several bullish catalysts working in its favor that we believe will help make it a significant winner for our members:
The biotech sector as a whole has been on fire, and is up over +20% since December 24th.
Strong corporate leadership led by CEO Denis Coran.
A growing pipeline and strategy that mitigates risk & drives shareholder value.
Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.
QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3.
QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential.
QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.
Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th.
At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility.
Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally!
This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!
This would be huge news, and could have a major impact on QBIO's stock price.
This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment.
We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace.
Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value.
This has the potential to be our next big winner of Q1 2019.
As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
About Q BioMed
Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.
QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.
Q BioMed Unlocks Undiscovered Biomedical Value
Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
Licenses or acquires the assets and works together to create valuation growth
How Q BioMed Accelerates Biomedical Technology Development
Unlocks capital in US public markets to fund the development of assets
Makes liquid investments in high-value assets that can produce exponential returns
Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships
Recent Developments
Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001
On Wednesday, QBIO announced that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
Dr. Ventola serves as a clinical psychologist and assistant professor at Yale University's Child Study Center with a clinical and research focus in: behavioral treatment for autism spectrum disorders, Pivotal Response Treatment (PRT), biological markers of treatment response, and dissemination and implementation of treatment for ASD. Dr. Ventola also directs the Rare Disease and Pediatric Center of Excellence at Cogstate, a publicly traded company that supports pharmaceutical companies in clinical trial design, methodologies, and rater training services as it relates to cognitive and other clinical outcome assessments.
Strategy and Clinical Trial Design Specialist Provides Expertise for the Clinical Trial Design and Regulatory Requirements of QBM-001
QBM-001 Developed to Treat a Pediatric Non-Verbal Disorder which impacts 18,000 children each year in the U.S and a similar amount in Europe.
Market Outlook
The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
Bone Metatases from Prostate and Breast Cancer
450,000 new breast and prostate cancer diagnoses each year
1 in 3 people will develop bone metastases from the spread of breast and prostate cancer
Pediatric Non-Verbal Disorder
Among the >60,000 US children who develop Autism Spectrum Disorders (ASD)
every year,
20,000 become nonverbal and will have to rely on assisted living for the rest of
their life.
Liver Cancer
700,000 patients worldwide
Short 1-year survival rate
Estimated 39,230 adults in the US will be diagnosed every year
Glaucoma
60 million patients worldwide
8 million with bilateral blindness
Typically no early warning signs
Therapy only slows progression, no cure
Technical Analysis
QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk.
CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend.
QBIO is trading well off its 52-week high, with plenty of room to the upside.
In fact, a run back to its 52-week high of $4.50 would represent a gain of over +154%!
The float on QBIO is also very thin at just $1.77, so don't be surprised if we see a big move from this ticker tomorrow.
As we stated above, this could easily be our next big winner of Q1 2019.
We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Comment:
Comment:
BULLISH SCENERIO!!